A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas
Clinical trial NCT03218072 · COMPLETED
Trial details
- NCT number
- NCT03218072
- Sponsor
- Shanghai Henlius Biotech
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-05-04
- Primary completion
- 2015-01-31
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.